中年良性前列腺增生患者性激素水平与胰岛素抵抗的相关性分析

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1018 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To analyze the correlation between sex hormone levels and insulin resistance in middle-aged patients with benign prostatic hyperplasia (BPH). Methods The clinical data of 135 middle-aged male patients with BPH who participated in physical examination in a top three hospital from January 2020 to December 2022 were retrospectively analyzed, and according to the level of the insulin resistance index (HOMA-IR), 55 cases in the BPH insulin resistance (IR) group (HOMA-IR>2.69) and 80 cases in the BPH non-IR group (HOMA-IR≤2.69) were included, respectively. General data, sex hormone indexes and glucose metabolism indexes were compared between the two groups. The correlation between sex hormone levels and glucose metabolism indexes was analyzed. Results The levels of FBG, INS and HOMA-IR in IR group were higher than those in non-IR group, serum T and FSH levels were lower than those in non-IR group, E₂ and E₂/T levels were higher than those in non-IR group. Serum testosterone (T) showed a significant negative correlation with HbA1c (r=-0.27,P=0.002), HOMA-IR (r=-0.23,P=0.007), and serum T was negatively correlated with fasting insulin (FINS) (r=-0.20,P=0.021). Serum estradiol (E₂) was positively correlated with FINS (r=0.19,P=0.023) and HOMA-IR (r=0.18,P=0.041), and E2/T was significantly positively correlated with FINS (r=0.30,P<0.001) and HOMA-IR (r=0.30,P<0.001). Serum follicle-stimulating hormone (FSH) was negatively correlated with FINS (r=-0.25, P=0.004) and HOMA-IR (r=-0.25,P=0.004); serum prolactin was negatively correlated with fasting blood glucose (r=-0.21,P=0.013). Conclusions Insulin resistance may be related with the levels of various sex hormones in middle-aged BPH patients, which has some clinical value for BPH prevention.

Key words： benign prostatic hyperplasia testosterone estradiol insulin resistance

Received: 09 June 2023

ZTFLH:

R697.32

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	PANG Aibo
	LYU Jungang
	HUANG Wei
	LING Cunbao
	LIN Fandan
	ZHANG Chunyan
	TIAN Yaping

Cite this article:

PANG Aibo,LYU Jungang,HUANG Wei等. Correlation between sex hormone levels and insulin resistance in middle-aged patients with benign prostatic hyperplasia[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2023, 34(12): 1050-1054.

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2023/V34/I12/1050

[1]	Franco J V A, Jung J H,Imamura M, et al.Minimally invasive treatments for benign prostatic hyperplasia:a Cochrane network meta-analysis[J]. BJU Int, 2022, 130(2): 142-156.
[2]	Krysiak R, Kowalcze K, Okopień B.Hypothalamic-pituitarygonadal axis and sexual functioning in metformin-treated men after discontinuation of testosterone replacement therapy: a pilot study[J].J Clin Pharm Ther, 2021, 46(6): 1764-1775.
[3]	中华医学会男科学分会,良性前列腺增生诊疗及健康管理指南编写组.良性前列腺增生诊疗及健康管理指南[J].中华男科学杂志, 2022, 28(4): 356-365.
[4]	GBD 2019 Benign Prostatic Hyperplasia Collaborators. The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: a systematic analysis for the Global Burden of Disease Study [J].Lancet Healthy Longev, 2022, 3(11): e754-e776.
[5]	Qian S, Zhang S, Xia W, et al.Correlation of prostatic morphological parameters and clinical progression in aging Chinese men with benign prostatic hyperplasia: Results from a cross-sectional study[J]. Prostate,2021, 81(8): 478-486.
[6]	李曼,涂美英,王先令,等.成年特发性低促性腺激素性性腺功能减退症1例[J].武警医学,2023,34(7): 616-618.
[7]	童梦霞.血清CTRP3、CTRP15水平与多囊卵巢综合征患者胰岛素抵抗的相关性研究[D].遵义:遵义医科大学, 2021.
[8]	Sorokina I V, Zhukova N A, Meshkova Y V, et al. Modeling of benign prostatic hyperplasia in rats with a high dose of testosterone[J].Bull Exp Biol Med, 2022,173(5): 680-686.
[9]	胡欣,韩雪,相萍萍,等.男性迟发性性腺功能减退症:指南与争议[J].中华内分泌代谢杂志, 2022, 38(5): 364-368.
[10]	王波,田野,班勇,等.雌雄激素水平、良性前列腺增生、前列腺炎的关系[J].医学综述, 2022, 28(7): 1285-1289.
[11]	逄瑷博,张春燕,凌存保,等.5-α还原酶抑制剂联合治疗良性前列腺增生的研究进展[J].武警医学,2023, 34(1):78-82.
[12]	王波,罗光恒,王振,等.不同比例浓度雌雄激素诱导下大鼠前列腺炎症反应模型的建立[J].四川大学学报(医学版), 2021, 52(3): 477-484.
[13]	白小岗,李霞贾爱华,等.2型糖尿病男性患者性激素水平与体重指数、糖脂代谢及胰岛素抵抗相关性分析[J].陕西医学杂志, 2022, 51(9): 1086-1089.
[14]	刘新明.成人垂体功能减退症及其激素替代治疗对糖脂代谢的影响[D].长春:吉林大学, 2022.
[15]	Lee S H, Park S Y, Choi C S. Insulin resistance: from mechanisms to therapeutic strategies[J]. Diabetes Metab J,2022, 46(1): 15-37.
[16]	Zhong W, Mao Y.Daily insulin dose and cancer risk among patients with type 1 diabetes[J].JAMA Oncol,2022, 8(9):1356-1358.
[17]	Ansarullah,Jain C,Far F F,et al.Inceptor counteracts insulin signalling in β-cells to control glycaemia[J].Nature,2021,590(7845): 326-331.
[18]	赵彩云,葛士俊,赵阿曼.稳态模型评估的胰岛素抵抗指数与多囊卵巢综合征患者血清性激素水平的相关性[J].河南医学研究, 2022, 31(12): 2212-2216.
[19]	Li J,Peng L,Cao D,et al.The association between metabolic syndrome and benign prostatic hyperplasia: a systematic review and meta-analysis[J]. Aging Male, 2020, 23(5): 1388-1399.
[20]	Yin L J,Wang X H.Research advance in the effects of androgen and its receptor on the development of obesity, obesity-related diseases and disorders of glucose and lipid metabolism[J].Sheng Li Xue Bao,2018,70(3): 319-328.
[21]	包宇航,郑仁东.糖代谢与睾酮关系的研究进展[J].实用老年医学, 2022, 36(8): 850-853.
[22]	冀远,王璟琦.胰岛素抵抗与男性功能性性腺功能减退相关性的研究进展[J].中国男科学杂志,2022, 36(4): 96-100.
[23]	Bengtsen M B, Heide-Jørgensen U, Borre M, et al.Acute urinary retention in men:21-year trends in incidence, subsequent benign prostatic hyperplasia-related treatment and mortality:a danish population-based cohort study[J].Prostate,2023, 83(1): 87-96.